Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.
- Authors
- Van Deerlin, Vivianna M; Sleiman, Patrick M A; Martinez-Lage, Maria; Chen-Plotkin, Alice; Wang, Li-San; Graff-Radford, Neill R; Dickson, Dennis W; Rademakers, Rosa; Boeve, Bradley F; Grossman, Murray; Arnold, Steven E; Mann, David M A; Pickering-Brown, Stuart M; Seelaar, Harro; Heutink, Peter; van Swieten, John C; Murrell, Jill R; Ghetti, Bernardino; Spina, Salvatore; Grafman, Jordan; Hodges, John; Spillantini, Maria Grazia; Gilman, Sid; Lieberman, Andrew P; Kaye, Jeffrey A; Woltjer, Randall L; Bigio, Eileen H; Mesulam, Marsel; Al-Sarraj, Safa; Troakes, Claire; Rosenberg, Roger N; White, Charles L; Ferrer, Isidro; LladΓ³, Albert; Neumann, Manuela; Kretzschmar, Hans A; Hulette, Christine Marie; Welsh-Bohmer, Kathleen A; Miller, Bruce L; Alzualde, Ainhoa; Lopez de Munain, Adolfo; McKee, Ann C; Gearing, Marla; Levey, Allan I; Lah, James J; Hardy, John; Rohrer, Jonathan D; Lashley, Tammaryn; Mackenzie, Ian R A; Feldman, Howard H; Hamilton, Ronald L; Dekosky, Steven T; van der Zee, Julie; Kumar-Singh, Samir; Van Broeckhoven, Christine; Mayeux, Richard; Vonsattel, Jean Paul G; Troncoso, Juan C; Kril, Jillian J; Kwok, John B J; Halliday, Glenda M; Bird, Thomas D; Ince, Paul G; Shaw, Pamela J; Cairns, Nigel J; Morris, John C; McLean, Catriona Ann; DeCarli, Charles; Ellis, William G; Freeman, Stefanie H; Frosch, Matthew P; Growdon, John H; Perl, Daniel P; Sano, Mary; Bennett, David A; Schneider, Julie A; Beach, Thomas G; Reiman, Eric M; Woodruff, Bryan K; Cummings, Jeffrey; Vinters, Harry V; Miller, Carol A; Chui, Helena C; Alafuzoff, Irina; Hartikainen, PΓ€ivi; Seilhean, Danielle; Galasko, Douglas; Masliah, Eliezer; Cotman, Carl W; TuΓ±Γ³n, M Teresa; MartΓnez, M Cristina Caballero; Munoz, David G; Carroll, Steven L; Marson, Daniel; Riederer, Peter F; Bogdanovic, Nenad; Schellenberg, Gerard D; Hakonarson, Hakon; Trojanowski, John Q; Lee, Virginia M-Y
- Year
- 2010
- Journal
- Nature genetics
- PMID
- 20154673
- DOI
- 10.1038/ng.536
- PMCID
- PMC2828525
Frontotemporal lobar degeneration (FTLD) is the second most common cause of presenile dementia. The predominant neuropathology is FTLD with TAR DNA-binding protein (TDP-43) inclusions (FTLD-TDP). FTLD-TDP is frequently familial, resulting from mutations in GRN (which encodes progranulin). We assembled an international collaboration to identify susceptibility loci for FTLD-TDP through a genome-wide association study of 515 individuals with FTLD-TDP. We found that FTLD-TDP associates with multiple SNPs mapping to a single linkage disequilibrium block on 7p21 that contains TMEM106B. Three SNPs retained genome-wide significance following Bonferroni correction (top SNP rs1990622, P = 1.08 x 10(-11); odds ratio, minor allele (C) 0.61, 95% CI 0.53-0.71). The association replicated in 89 FTLD-TDP cases (rs1990622; P = 2 x 10(-4)). TMEM106B variants may confer risk of FTLD-TDP by increasing TMEM106B expression. TMEM106B variants also contribute to genetic risk for FTLD-TDP in individuals with mutations in GRN. Our data implicate variants in TMEM106B as a strong risk factor for FTLD-TDP, suggesting an underlying pathogenic mechanism.
Region of genome-wide association at 7p21a. Manhattan plot of βlog10(observed P-value) across genome demonstrating region of genome-wide significant association on chromosome 7; b. Regional plot of the TMEM106B associated interval. Foreground plot: Scatter plot of the βlog10 P-values plotted against physical position (NCBI build 36). Background Plot: Estimated recombination rates (from phase 2 of the HapMap) plotted to reflect the local LD structure. The color of the dots represents the strength of LD between the top SNP rs1990622, and its proxies (red: r2 β₯ 0.8; orange 0.8 < r2 β₯ 0.4; blue < 0.4). Gene annotations were obtained from assembly 18 of the UCSC genome browser; c. Location of 3 highest associated SNPs (green arrows) relative to the gene structure of TMEM106B (blue bars, 3β² and 5β²-untranslated regions; larger red bars, coding exons; thick gray line, intronic regions; gray dashed line, downstream chromosome sequence) and chromosome 7 location.
TMEM106B expression variation by genotype and disease statea. TMEM106B mRNA expression by QRT-PCR in frontal cortex differed significantly by genotype at rs1990622 (overall P=0.027, genotype TT vs. TC P=0.017, TT vs. CC P=0.03). Black circles, FTLD-TDP (n=18); open squares, normal (n=7); horizontal lines, group mean. Significance of P-values are denoted by the numbers of asterisks. b. TMEM106B mRNA expression in frontal cortex was significantly higher in samples from FTLD-TDP patients compared to normal controls (P=0.045). c. TMEM106B expression in frontal cortex samples in FTLD-TDP with (GRN pos, n=8) or without (GRN neg, n=10) GRN mutations compared to normals (n=7). GRN mutation carriers had significantly higher levels of TMEM106B expression (overall P =0.0009, GRN pos vs. controls P =0.0005, GRN pos vs. GRN neg P =0.002). d. When only cases heterozygous at rs1990622 (n=14) were evaluated, GRN mutations remained significantly associated with a higher level of TMEM106B expression (P =0.039) in frontal cortex. QRT-PCR was performed in triplicate for all expression studies. Expression values were normalized to the geometric mean of two housekeeping genes and are shown relative to a single reference normal control sample23. Error bars represent the standard error of the mean. Normalized gene expression data and sample genotype and gender data used for these analyses are provided online in Supplementary Material.
Manhattan plot in cases with and without GRN mutationsManhattan plot of βlog10(observed P-value) across genome in cases with (a) and without (b) GRN mutations. The subset of cases with GRN mutations demonstrates regions of genome-wide significant association on chromosomes 7 and 17. The chr 17 association is confirmed to be driven by a shared haplotype in c.1477C>T (p.R493X) GRN mutation carriers representing ~20% of mutation positive cases, however the chromosome 7 association is not related to any single GRN mutation and remains when the cases with c.1477C>T are removed (P=1.446Γ10β10). The same locus on chr 7 identified in the GRN mutation cases is also the strongest signal in the GRN negative cases, although it does not reach genome-wide significance. A list of the SNPs with the highest signals in b is given in Supplementary Table 8.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genome-wide association study of Tourette's syndrome. | 2013 | 22889924 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| GWAS SVatalog: a visualization tool to aid fine-mapping of GWAS loci with structural variations. | Chirmade S et al. | β | 2026 | β |
| TDP-43 proteinopathies and neurodegeneration: insights from Caenorhabditis elegans models. | Pir GJ et al. | β | 2026 | β |
| The causal effects of dementia on systemic sclerosis: a two-sample bidirectional Mendelian randomization study. | Xiao J et al. | β | 2026 | β |
| Understanding Neurodegenerative Diseases From the -Omics Perspective: Lessons Learnt. | Ibanez L et al. | β | 2026 | β |
| Association between osteoarthritis and cognitive function: results from the NHANES 2011-2014 and Mendelian randomization study. | Zhao K et al. | β | 2025 | β |
| Causal associations between cognitive impairments and retinal diseases: A two-sample Mendelian randomization study. | Shi Q et al. | β | 2025 | β |
| Causal relationship between schizophrenia and five types of dementia: A bidirectional two-sample Mendelian randomization study. | Tao F et al. | β | 2025 | β |
| Challenges of modelling TDP-43 pathology in mice. | Armas JMB et al. | β | 2025 | β |
| Combining GWAS Summary Data and Proteomics Identified Potential Drug Targets in Dementia. | Zhao Y et al. | β | 2025 | β |
| Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing. | Pottier C et al. | β | 2025 | β |
| Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study. | Mirza SS et al. | β | 2025 | β |
| Divergent and convergent TMEM106B pathology in murine models of neurodegeneration and human disease. | Du M et al. | β | 2025 | β |
| DNA methylation as a contributor to dysregulation of STX6 and other frontotemporal Lobar degeneration genetic risk-associated loci. | Rambarack N et al. | β | 2025 | β |
| Genetic variation in TMEM106B alters microglial activation and cytokine responses in chronic traumatic encephalopathy. | Hartman S et al. | β | 2025 | β |
| Genome-wide association studies of TDP-43 proteinopathy and hippocampal sclerosis reveal shared genetic associations with APOE and TMEM106B. | Godrich D et al. | β | 2025 | β |
| Human and mouse proteomics reveals the shared pathways in Alzheimer's disease and delayed protein turnover in the amyloidome. | Yarbro JM et al. | β | 2025 | β |
| Identification of novel therapeutic targets for cognitive performance and associations with brain health. | Zhang LY et al. | β | 2025 | β |
| Increased TMEM106B levels lead to lysosomal dysfunction which affects synaptic signaling and neuronal health. | Perneel J et al. | β | 2025 | β |
| Investigating causal effects of HDL-C on cognitive function through cross-sectional and Mendelian randomization analyses: concentration-response patterns and clues for Alzheimer's disease prevention. | Fan L et al. | β | 2025 | β |
| LncRNA-induced lysosomal localization of NHE1 promotes increased lysosomal pH in macrophages leading to atherosclerosis. | Shi P et al. | β | 2025 | β |
| Lysosomal Channels as New Molecular Targets in the Pharmacological Therapy of Neurodegenerative Diseases <i>via</i> Autophagy Regulation. | Tedeschi V et al. | β | 2025 | β |
| Multiplex neurodegeneration proteotoxicity platform reveals DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity. | Resnick SJ et al. | β | 2025 | β |
| Myristoylation of TMEM106B by NMT1/2 regulates TMEM106B trafficking and turnover. | Lacrampe A et al. | β | 2025 | β |
| PGRN as an emerging regulator of lipid metabolism in neurodegenerative diseases. | Shi Y et al. | β | 2025 | β |
| Physiological shedding and C-terminal proteolytic processing of TMEM106B. | Held S et al. | β | 2025 | β |
| Plasma glial fibrillary acidic protein and neurological diseases: A bidirectional Mendelian randomization study. | Jiang D et al. | β | 2025 | β |
| Polygenic associations with clinical and neuropathological trait heterogeneity across TDP-43 proteinopathies. | Spencer BE et al. | β | 2025 | β |
| Progranulin deficiency does not exacerbate TDP-43 pathology in TDP-43 transgenic mouse models. | Yang C et al. | β | 2025 | β |
| Progranulin deficiency in the brain: the interplay between neuronal and non-neuronal cells. | Gaweda-Walerych K et al. | β | 2025 | β |
| Protein aggregation in neurodegenerative diseases. | Wang J et al. | β | 2025 | β |
| Rethinking the link between gestational diabetes and dementia risk. | Xu QH et al. | β | 2025 | β |
| RNA-binding proteins in ALS and FTD: from pathogenic mechanisms to therapeutic insights. | Rummens J et al. | β | 2025 | β |
| Shared genes and pathways in dementia: Insights from genome-wide association studies. | Loi KJ et al. | β | 2025 | β |
| TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes. | Zeng Y et al. | β | 2025 | β |
| The role of autophagy in the pathogenesis and treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). | Beckers J et al. | β | 2025 | β |
| The role of endolysosomal progranulin and TMEM106B in neurodegenerative diseases. | Takahashi H et al. | β | 2025 | β |
| The role of the hippocampus and SLC39A8 in chronic musculoskeletal pain-induced dementia: a Mendelian randomization study. | Du K et al. | β | 2025 | β |
| TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy in transgenic Caenorhabditis elegans. | Riordan R et al. | β | 2025 | β |
| TMEM106B deficiency leads to alterations in lipid metabolism and obesity in the TDP-43<sup>Q331K</sup> knock-in mouse model. | Yang C et al. | β | 2025 | β |
| TMEM106B Knockdown Exhibits a Neuroprotective Effect in Parkinson's Disease via Decreasing Inflammation and Iron Deposition. | Liu Y et al. | β | 2025 | β |
| A 3'UTR Insertion Is a Candidate Causal Variant at the <i>TMEM106B</i> Locus Associated With Increased Risk for FTLD-TDP. | Chemparathy A et al. | β | 2024 | β |
| Accumulation of TMEM106B C-terminal fragments in Niemann-Pick type C disease. | Azaria RD et al. | β | 2024 | β |
| A common Alu insertion in the 3'UTR of TMEM106B is associated with risk of dementia. | Rodney A et al. | β | 2024 | β |
| Association between adding salt in food and dementia in European descent: A mendelian randomization study. | Zhou R et al. | β | 2024 | β |
| Association between dementia, Alzheimer's disease, and liver cancer: A Mendelian randomization analysis. | Li T et al. | β | 2024 | β |
| Association of TMEM106B with Cortical <i>APOE</i> Gene Expression in Neurodegenerative Conditions. | Picard C et al. | β | 2024 | β |
| Causal relationship between dementia and delirium: Insights from a bidirectional two-sample Mendelian randomization analysis. | Cai Y et al. | β | 2024 | β |
| Cell subtype-specific effects of genetic variation in the Alzheimer's disease brain. | Fujita M et al. | β | 2024 | β |
| Cleaved TMEM106B forms amyloid aggregates in central and peripheral nervous systems. | Bacioglu M et al. | β | 2024 | β |
| Cognitively healthy centenarians are genetically protected against Alzheimer's disease. | Tesi N et al. | β | 2024 | β |
| Cognitive resilience to Alzheimer's disease characterized by cell-type abundance. | O'Neill N et al. | β | 2024 | β |
| Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia. | Reus LM et al. | β | 2024 | β |
| Cryo-EM structures of pathogenic fibrils and their impact on neurodegenerative disease research. | Todd TW et al. | β | 2024 | β |
| Disruptions in axonal lysosome transport and its contribution to neurological disease. | Paumier JM et al. | β | 2024 | β |
| Gaps in biomedical research in frontotemporal dementia: A call for diversity and disparities focused research. | Nuytemans K et al. | β | 2024 | β |
| Gene replacement-Alzheimer's disease (GR-AD): Modeling the genetics of human dementias in mice. | Benzow K et al. | β | 2024 | β |
| Gene-Specific Effects on Brain Volume and Cognition of <i>TMEM106B</i> in Frontotemporal Lobar Degeneration. | Vandebergh M et al. | β | 2024 | β |
| Genetics and Neuropathology of Neurodegenerative Dementias. | Scholz SW et al. | β | 2024 | β |
| Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia. | Manzoni C et al. | β | 2024 | β |
| Hypomyelination Leukodystrophy 16 (HLD16)-Associated Mutation p.Asp252Asn of TMEM106B Blunts Cell Morphological Differentiation. | Sawaguchi S et al. | β | 2024 | β |
| Limbic-predominant age-related TDP-43 encephalopathy (LATE-NC): Co-pathologies and genetic risk factors provide clues about pathogenesis. | Nelson PT et al. | β | 2024 | β |
| Loss of TMEM106B exacerbates Tau pathology and neurodegeneration in PS19 mice. | Feng T et al. | β | 2024 | β |
| Lysosomal membrane protein TMEM106B modulates hematopoietic stem and progenitor cell proliferation and differentiation by regulating LAMP2A stability. | Guo D et al. | β | 2024 | β |
| Lysosomal TMEM106B interacts with galactosylceramidase to regulate myelin lipid metabolism. | Takahashi H et al. | β | 2024 | β |
| Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. | Nixon RA et al. | β | 2024 | β |
| Mendelian Randomization Analysis to Assess Whether Magnetic Resonance Imaging Signs of Cerebral Small Vessel Disease Can Cause Cognitive Decline and Dementia. | Liu L et al. | β | 2024 | β |
| Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study. | Li YS et al. | β | 2024 | β |
| Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration. | Reich M et al. | β | 2024 | β |
| Physiological and pathological functions of TMEM106B in neurodegenerative diseases. | Zhu M et al. | β | 2024 | β |
| Potential Biomarkers in Cerebrospinal Fluid and Plasma for Dementia. | He Q et al. | β | 2024 | β |
| Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease. | Western D et al. | β | 2024 | β |
| Risk and progression of frontotemporal dementia in carriers of the TMEM106B protective genotype and its relationship with TDP-43 pathology. | Gomes KB | β | 2024 | β |
| The concept of resilience to Alzheimer's Disease: current definitions and cellular and molecular mechanisms. | de Vries LE et al. | β | 2024 | β |
| The Underestimated Role of Iron in Frontotemporal Dementia: A Narrative Review. | Ferretti S et al. | β | 2024 | β |
| TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy. | Edwards GA et al. | β | 2024 | β |
| TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia. | Marks JD et al. | β | 2024 | β |
| Tracing TMEM106B fibril deposition in aging and Parkinson's disease with dementia brains. | Zhao W et al. | β | 2024 | β |
| Two novel variants in GRN: the relevance of CNV analysis and genetic screening in FTLD patients with a negative family history. | De Houwer JFH et al. | β | 2024 | β |
| AAV-<i>GRN</i> partially corrects motor deficits and ALS/FTLD-related pathology in <i>Tmem106b</i><sup><i>-/-</i></sup><i>Grn</i><sup><i>-/-</i></sup> mice. | Feng T et al. | β | 2023 | β |
| Accelerating Alzheimer's therapeutic development: The past and future of clinical trials. | Boxer AL et al. | β | 2023 | β |
| Accumulation of TMEM106B C-terminal fragments in neurodegenerative disease and aging. | Perneel J et al. | β | 2023 | β |
| Advances in sequencing technologies for amyotrophic lateral sclerosis research. | Udine E et al. | β | 2023 | β |
| A two-sample Mendelian randomization study of atherosclerosis and dementia. | Zhang Q et al. | β | 2023 | β |
| Case report: TMEM106B haplotype alters penetrance of GRN mutation in frontotemporal dementia family. | Perneel J et al. | β | 2023 | β |
| Correlating the Structure and Gene Silencing Activity of Oligonucleotide-Loaded Lipid Nanoparticles Using Small-Angle X-ray Scattering. | Hammel M et al. | β | 2023 | β |
| C-terminal TMEM106B fragments in human brain correlate with disease-associated TMEM106B haplotypes. | T Vicente C et al. | β | 2023 | β |
| Detection and discovery of repeat expansions in ataxia enabled by next-generation sequencing: present and future. | Rafehi H et al. | β | 2023 | β |
| Frontotemporal Dementia, Where Do We Stand? A Narrative Review. | Antonioni A et al. | β | 2023 | β |
| Frontotemporal lobar degeneration. | Grossman M et al. | β | 2023 | β |
| Genetic Insights into the Risk of Metabolic Syndrome and Its Components on Dementia: A Mendelian Randomization. | He Q et al. | β | 2023 | β |
| Identification of a de novo Mutation in TMEM106B in a Saudi Child Causes Hypomyelination Leukodystrophy. | Alotaibi L et al. | β | 2023 | β |
| Identification of region-specific splicing QTLs in human hippocampal tissue and its distinctive role in brain disorders. | Li X et al. | β | 2023 | β |
| Inflammation and neuronal gene expression changes differ in early versus late chronic traumatic encephalopathy brain. | Labadorf A et al. | β | 2023 | β |
| Lack of a protective effect of the Tmem106b "protective SNP" in the Grn knockout mouse model for frontotemporal lobar degeneration. | Cabron AS et al. | β | 2023 | β |
| Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases. | Nag S et al. | β | 2023 | β |
| Limbic-predominant age-related TDP-43 proteinopathy (LATE-NC) is associated with abundant TMEM106B pathology. | Neumann M et al. | β | 2023 | β |
| Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection. | Byrnes AE et al. | β | 2023 | β |
| Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia. | Simon MJ et al. | β | 2023 | β |
| Mobile element variation contributes to population-specific genome diversification, gene regulation and disease risk. | Kojima S et al. | β | 2023 | β |
| Molecular fragment characteristics and distribution of tangle associated TDP-43 (TATs) and other TDP-43 lesions in Alzheimer's disease. | Josephs KA et al. | β | 2023 | β |
| Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. | Scheres SHW et al. | β | 2023 | β |
| Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer's and coronary disease pathways. | Wang L et al. | β | 2023 | β |
| Progranulin deficiency results in sex-dependent alterations in microglia in response to demyelination. | Zhang T et al. | β | 2023 | β |
| Relationship of Klotho with cognition and dementia: Results from the NHANES 2011-2014 and Mendelian randomization study. | Wu Y et al. | β | 2023 | β |
| Shared genetic risk loci between Alzheimer's disease and related dementias, Parkinson's disease, and amyotrophic lateral sclerosis. | Wainberg M et al. | β | 2023 | β |
| Superresolution live-cell imaging reveals that the localization of TMEM106B to filopodia in oligodendrocytes is compromised by the hypomyelination-related D252N mutation. | Xing S et al. | β | 2023 | β |
| The endolysosomal pathway and ALS/FTD. | Todd TW et al. | β | 2023 | β |
| The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus. | Lee JY et al. | β | 2023 | β |
| The role of plasma cortisol in dementia, epilepsy, and multiple sclerosis: A Mendelian randomization study. | Li H et al. | β | 2023 | β |
| The TMEM106B T186S coding variant increases neurite arborization and synaptic density in primary hippocampal neurons. | Nguyen Q et al. | β | 2023 | β |
| TMEM106B aggregation in neurodegenerative diseases: linking genetics to function. | Jiao HS et al. | β | 2023 | β |
| TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry. | Baggen J et al. | β | 2023 | β |
| TMEM106B Puncta Is Increased in Multiple Sclerosis Plaques, and Reduced Protein in Mice Results in Delayed Lipid Clearance Following CNS Injury. | Shafit-Zagardo B et al. | β | 2023 | β |
| TMEM106B reduction does not rescue GRN deficiency in iPSC-derived human microglia and mouse models. | Dominguez SL et al. | β | 2023 | β |
| TMEM106B regulates microglial proliferation and survival in response to demyelination. | Zhang T et al. | β | 2023 | β |
| Age-dependent formation of TMEM106B amyloid filaments in human brains. | Schweighauser M et al. | β | 2022 | β |
| Amyloid fibrils in FTLD-TDP are composed of TMEM106B and not TDP-43. | Jiang YX et al. | β | 2022 | β |
| An unexpected protein aggregate in diseased and ageing brains. | Takahashi H et al. | β | 2022 | β |
| Association between risk polymorphisms for neurodegenerative diseases and cognition in colombian patients with frontotemporal dementia. | LΓ³pez-CΓ‘ceres A et al. | β | 2022 | β |
| Body Complexion and Circulating Lipids in the Risk of TDP-43 Related Disorders. | Esteban-GarcΓa N et al. | β | 2022 | β |
| Causal association between systemic lupus erythematosus and the risk of dementia: A Mendelian randomization study. | Jin T et al. | β | 2022 | β |
| Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders. | Bryois J et al. | β | 2022 | β |
| Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. | Benussi A et al. | β | 2022 | β |
| Dissecting the clinical heterogeneity of early-onset Alzheimer's disease. | Sirkis DW et al. | β | 2022 | β |
| Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. | Uemura MT et al. | β | 2022 | β |
| Emerging cellular themes in leukodystrophies. | Nowacki JC et al. | β | 2022 | β |
| Flying under the radar: TMEM106B(120-254) fibrils break out in diverse neurodegenerative disorders. | Copley KE et al. | β | 2022 | β |
| Frontotemporal degeneration genetic risk loci and transcription regulation as a possible mechanistic link to disease risk. | Sawyer RP et al. | β | 2022 | β |
| Generic amyloid fibrillation of TMEM106B in patient with Parkinson's disease dementia and normal elders. | Fan Y et al. | β | 2022 | β |
| Genetics of cognitive dysfunction in Parkinson's disease. | Wise AH et al. | β | 2022 | β |
| Genome-wide association studies for Alzheimer's disease: bigger is not always better. | Escott-Price V et al. | β | 2022 | β |
| Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes. | Prater KE et al. | β | 2022 | β |
| Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. | Chang A et al. | β | 2022 | β |
| Identification of TMEM106B amyloid fibrils provides an updated view of TMEM106B biology in health and disease. | Perneel J et al. | β | 2022 | β |
| Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers. | Duong MT et al. | β | 2022 | β |
| Loss of TMEM106B exacerbates C9ALS/FTD DPR pathology by disrupting autophagosome maturation. | Bauer CS et al. | β | 2022 | β |
| <i>TMEM106B</i> Acts as a Modifier of Cognitive and Motor Functions in Amyotrophic Lateral Sclerosis. | Manini A et al. | β | 2022 | β |
| Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. | Udayar V et al. | β | 2022 | β |
| Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. | Riku Y et al. | β | 2022 | β |
| Neuroimmune dysfunction in frontotemporal dementia: Insights from progranulin and C9orf72 deficiency. | Hashimoto K et al. | β | 2022 | β |
| Neuronal endolysosomal transport and lysosomal functionality in maintaining axonostasis. | Roney JC et al. | β | 2022 | β |
| New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia. | Amin S et al. | β | 2022 | β |
| Protein interaction network analysis reveals genetic enrichment of immune system genes in frontotemporal dementia. | KoΓ§oΔlu C et al. | β | 2022 | β |
| Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. | Pottier C et al. | β | 2022 | β |
| Synaptic proteomics reveal distinct molecular signatures of cognitive change and C9ORF72 repeat expansion in the human ALS cortex. | Laszlo ZI et al. | β | 2022 | β |
| TDP-43 pathology: From noxious assembly to therapeutic removal. | Keating SS et al. | β | 2022 | β |
| TMEM106B deficiency impairs cerebellar myelination and synaptic integrity with Purkinje cell loss. | Feng T et al. | β | 2022 | β |
| TMEM106B in humans and Vac7 and Tag1 in yeast are predicted to be lipid transfer proteins. | Levine TP | β | 2022 | β |
| Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration. | Shao W et al. | β | 2022 | β |
| Uncovering the impact of noncoding variants in neurodegenerative brain diseases. | Frydas A et al. | β | 2022 | β |
| 7p21.3 Together With a 12p13.32 Deletion in a Patient With Microcephaly-Does 12p13.32 Locus Possibly Comprises a Candidate Gene Region for Microcephaly? | Rincic M et al. | β | 2021 | β |
| Aged Tmem106b knockout mice display gait deficits in coincidence with Purkinje cell loss and only limited signs of non-motor dysfunction. | Stroobants S et al. | β | 2021 | β |
| A growth-factor-activated lysosomal K<sup>+</sup> channel regulates Parkinson's pathology. | Wie J et al. | β | 2021 | β |
| A Mendelian Randomization Study of Plasma Homocysteine Levels and Cerebrovascular and Neurodegenerative Diseases. | Liu W et al. | β | 2021 | β |
| A novel temporal-predominantΒ neuro-astroglial tauopathyΒ associated with TMEM106B gene polymorphism in FTLD/ALS-TDP. | Llibre-Guerra JJ et al. | β | 2021 | β |
| Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. | Pang W et al. | β | 2021 | β |
| Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration. | Massimo L et al. | β | 2021 | β |
| Delineating the Genetic Component of Gene Expression in Major Depression. | Dall'Aglio L et al. | β | 2021 | β |
| Delivering progranulin to neuronal lysosomes protects against excitotoxicity. | Davis SE et al. | β | 2021 | β |
| Disease-related cortical thinning in presymptomatic granulin mutation carriers. | Borrego-Γcija S et al. | β | 2021 | β |
| Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases. | Perrone F et al. | β | 2021 | β |
| Fronto-temporal dementia risk gene <i>TMEM106B</i> has opposing effects in different lysosomal storage disorders. | Perez-Canamas A et al. | β | 2021 | β |
| Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. | Reus LM et al. | β | 2021 | β |
| Genetic Overlap Between Alzheimer's Disease and Depression Mapped Onto the Brain. | Monereo-SΓ‘nchez J et al. | β | 2021 | β |
| Genome-wide analyses of smoking behaviors in schizophrenia: Findings from the Psychiatric Genomics Consortium. | Peterson RE et al. | β | 2021 | β |
| Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. | Reus LM et al. | β | 2021 | β |
| Loss of Tmem106b leads to cerebellum Purkinje cell death and motor deficits. | Rademakers R et al. | β | 2021 | β |
| Lysosomal Dysfunction and Other Pathomechanisms in FTLD: Evidence from Progranulin Genetics and Biology. | Zhou X et al. | β | 2021 | β |
| Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. | Root J et al. | β | 2021 | β |
| Mendelian and Sporadic FTD: Disease Risk and Avenues from Genetics to Disease Pathways Through In Silico Modelling. | Manzoni C et al. | β | 2021 | β |
| Molecular Pathways Involved in Frontotemporal Lobar Degeneration with TDP-43 Proteinopathy: What Can We Learn from Proteomics? | Mol MO et al. | β | 2021 | β |
| Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. | Vieira SRL et al. | β | 2021 | β |
| Neuronal Development-Related miRNAs as Biomarkers for Alzheimer's Disease, Depression, Schizophrenia and Ionizing Radiation Exposure. | Segaran RC et al. | β | 2021 | β |
| Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. | Feng T et al. | β | 2021 | β |
| rs1990622 variant associates with Alzheimer's disease and regulates TMEM106B expression in human brain tissues. | Hu Y et al. | β | 2021 | β |
| Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases. | Zhang F et al. | β | 2021 | β |
| SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. | Barbier M et al. | β | 2021 | β |
| TDP-43 Pathology in Alzheimer's Disease. | Meneses A et al. | β | 2021 | β |
| The Role of White Matter Dysfunction and Leukoencephalopathy/Leukodystrophy Genes in the Aetiology of Frontotemporal Dementias: Implications for Novel Approaches to Therapeutics. | Lok HC et al. | β | 2021 | β |
| TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. | Hong S et al. | β | 2021 | β |
| TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. | Mao F et al. | β | 2021 | β |
| Tweaking Progranulin Expression: Therapeutic Avenues and Opportunities. | Terryn J et al. | β | 2021 | β |
| Whole-exome sequencing of Finnish patients with vascular cognitive impairment. | MΓΆnkΓ€re S et al. | β | 2021 | β |
| ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. | Dai DL et al. | β | 2020 | β |
| A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination. | Feng T et al. | β | 2020 | β |
| Delineating the Genetic Component of Gene Expression in Major Depression | DallβAglio L et al. | β | 2020 | β |
| Functional genomics links genetic origins to pathophysiology in neurodegenerative and neuropsychiatric disease. | Wamsley B et al. | β | 2020 | β |
| Genetic architecture of common non-Alzheimer's disease dementias. | Guerreiro R et al. | β | 2020 | β |
| Genetic architecture of neurodegenerative dementias. | Clarimon J et al. | β | 2020 | β |
| Genetics of Chronic Traumatic Encephalopathy. | Abdolmohammadi B et al. | β | 2020 | β |
| Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology. | Yang HS et al. | β | 2020 | β |
| Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. | Huin V et al. | β | 2020 | β |
| Impairment of Lysosome Function and Autophagy in Rare Neurodegenerative Diseases. | Darios F et al. | β | 2020 | β |
| Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. | Feng T et al. | β | 2020 | β |
| Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin-deficient mice. | Zhou X et al. | β | 2020 | β |
| Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. | Zhou X et al. | β | 2020 | β |
| Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice. | Werner G et al. | β | 2020 | β |
| Omics in Neurodegenerative Disease: Hope or Hype? | Diaz-Ortiz ME et al. | β | 2020 | β |
| The complex relationship between genotype, pathology and phenotype in familial dementia. | Kwok JB et al. | β | 2020 | β |
| The FTLD Risk Factor TMEM106B Regulates the Transport of Lysosomes at the Axon Initial Segment of Motoneurons. | LΓΌningschrΓΆr P et al. | β | 2020 | β |
| The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. | Li Z et al. | β | 2020 | β |
| C9orf72-FTD/ALS pathogenesis: evidence from human neuropathological studies. | Vatsavayai SC et al. | β | 2019 | β |
| Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia. | Giannini LAA et al. | β | 2019 | β |
| Education modulates brain maintenance in presymptomatic frontotemporal dementia. | Gazzina S et al. | β | 2019 | β |
| Genetics and molecular mechanisms of frontotemporal lobar degeneration: an update and future avenues. | Ferrari R et al. | β | 2019 | β |
| Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. | Pottier C et al. | β | 2019 | β |
| Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. | Ciani M et al. | β | 2019 | β |
| Immune Signaling in Neurodegeneration. | Hammond TR et al. | β | 2019 | β |
| LATE to the PART-y. | Josephs KA et al. | β | 2019 | β |
| Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. | Nelson PT et al. | β | 2019 | β |
| Lysosome trafficking and signaling in health and neurodegenerative diseases. | Lie PPY et al. | β | 2019 | β |
| Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. | Josephs KA et al. | β | 2019 | β |
| Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD. | Hedl TJ et al. | β | 2019 | β |
| Recent advances in the genetics of frontotemporal dementia. | Sirkis DW et al. | β | 2019 | β |
| Recent advances in understanding frontotemporal degeneration. | Borroni B et al. | β | 2019 | β |
| Review: Clinical, genetic and neuroimaging features of frontotemporal dementia. | Convery R et al. | β | 2019 | β |
| Review: Modelling the pathology and behaviour of frontotemporal dementia. | Solomon DA et al. | β | 2019 | β |
| Review: Neuropathology of non-tau frontotemporal lobar degeneration. | Neumann M et al. | β | 2019 | β |
| Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. | Chornenkyy Y et al. | β | 2019 | β |
| TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy. | Zhang L et al. | β | 2019 | β |
| Therapeutic trial design for frontotemporal dementia and related disorders. | Desmarais P et al. | β | 2019 | β |
| The role of lysosomes and autophagosomes in frontotemporal lobar degeneration. | Bain HDC et al. | β | 2019 | β |
| TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. | Tropea TF et al. | β | 2019 | β |
| UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. | Placek K et al. | β | 2019 | β |
| Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing. | Goldman JS et al. | β | 2018 | β |
| Atypical parkinsonian syndromes: a general neurologist's perspective. | DeutschlΓ€nder AB et al. | β | 2018 | β |
| Clinical variability and onset age modifiers in an extended Belgian GRN founder family. | Wauters E et al. | β | 2018 | β |
| Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. | Koga S et al. | β | 2018 | β |
| Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE Ξ΅4 haplotype status: a community-based cohort study. | Yang HS et al. | β | 2018 | β |
| Fitting TDP-43 into the APOE Ξ΅4 and neurodegeneration story. | Josephs KA | β | 2018 | β |
| Frontotemporal dementia. | Deleon J et al. | β | 2018 | β |
| Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown. | Clayton EL et al. | β | 2018 | β |
| Genetic Modifiers in Neurodegeneration. | Jain N et al. | β | 2018 | β |
| In search of lost trafficking. | Bechek SC et al. | β | 2018 | β |
| Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity. | Nicholson AM et al. | β | 2018 | β |
| Molecular regulations and therapeutic targets of Gaucher disease. | Chen Y et al. | β | 2018 | β |
| Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency. | Arrant AE et al. | β | 2018 | β |
| Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. | Pottier C et al. | β | 2018 | β |
| Progranulin: Functions and neurologic correlations. | Townley RA et al. | β | 2018 | β |
| Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia. | Fenoglio C et al. | β | 2018 | β |
| Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum. | Karch CM et al. | β | 2018 | β |
| TDP-43 pathology in multiple system atrophy: colocalization of TDP-43 and Ξ±-synuclein in glial cytoplasmic inclusions. | Koga S et al. | β | 2018 | β |
| The Genetics of <i>C9orf72</i> Expansions. | Gijselinck I et al. | β | 2018 | β |
| The lysosomal function of progranulin,Β a guardian against neurodegeneration. | Paushter DH et al. | β | 2018 | β |
| The Post-GWAS Era: From Association to Function. | Gallagher MD et al. | β | 2018 | β |
| TMEM106B, a risk factor for FTLD and aging, has an intrinsically disordered cytoplasmic domain. | Kang J et al. | β | 2018 | β |
| TMEM106B haplotypes have distinct gene expression patterns in aged brain. | Ren Y et al. | β | 2018 | β |
| Variation in TMEM106B in chronic traumatic encephalopathy. | Cherry JD et al. | β | 2018 | β |
| A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression. | Gallagher MD et al. | β | 2017 | β |
| Adult neurogenesis and neurodegenerative diseases: A systems biology perspective. | Horgusluoglu E et al. | β | 2017 | β |
| A novel network analysis approach reveals DNA damage, oxidative stress and calcium/cAMP homeostasis-associated biomarkers in frontotemporal dementia. | Palluzzi F et al. | β | 2017 | β |
| Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy. | Hu T et al. | β | 2017 | β |
| C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease. | Amick J et al. | β | 2017 | β |
| Differential Aging Analysis in Human Cerebral Cortex Identifies Variants in TMEM106B and GRN that Regulate Aging Phenotypes. | Rhinn H et al. | β | 2017 | β |
| Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. | Koga S et al. | β | 2017 | β |
| Dominant LGMD2A: alternative diagnosis or hidden digenism? | SΓ‘enz A et al. | β | 2017 | β |
| Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency. | Zhou X et al. | β | 2017 | β |
| Factors influencing the age at onset in familial frontotemporal lobar dementia: Important weight of genetics. | Barbier M et al. | β | 2017 | β |
| Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study. | Steele NZ et al. | β | 2017 | β |
| Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. | Mann DMA et al. | β | 2017 | β |
| Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia. | Mishra A et al. | β | 2017 | β |
| Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. | Katsumata Y et al. | β | 2017 | β |
| HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort. | Yang X et al. | β | 2017 | β |
| Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. | White CC et al. | β | 2017 | β |
| Intracellular Proteolysis of Progranulin Generates Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal Dementia Caused by <i>GRN</i> Mutations. | Holler CJ et al. | β | 2017 | β |
| Latest emerging functions of SPP/SPPL intramembrane proteases. | Mentrup T et al. | β | 2017 | β |
| Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice. | Klein ZA et al. | β | 2017 | β |
| Modifiers of GRN-Associated Frontotemporal Lobar Degeneration. | Wauters E et al. | β | 2017 | β |
| Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? | De Vos KJ et al. | β | 2017 | β |
| [Pathomechanisms and clinical aspects of frontotemporal lobar degeneration]. | BΓΌrger K et al. | β | 2017 | β |
| Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. | Chitramuthu BP et al. | β | 2017 | β |
| Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. | Valdez C et al. | β | 2017 | β |
| Recent advances in the molecular genetics of frontotemporal lobar degeneration. | Rainero I et al. | β | 2017 | β |
| Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons. | Ali YO et al. | β | 2017 | β |
| The TMEM106B risk allele is associated with lower cortical volumes in a clinically diagnosed frontotemporal dementia cohort. | Harding SR et al. | β | 2017 | β |
| TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3). | Rostgaard N et al. | β | 2017 | β |
| Weighted Protein Interaction Network Analysis of Frontotemporal Dementia. | Ferrari R et al. | β | 2017 | β |
| ALS: A bucket of genes, environment, metabolism and unknown ingredients. | ZufirΓa M et al. | β | 2016 | β |
| A novel Alzheimer disease locus located near the gene encoding tau protein. | Jun G et al. | β | 2016 | β |
| A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy. | Sassi C et al. | β | 2016 | β |
| C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. | Amick J et al. | β | 2016 | β |
| Catastrophic cliffs: a partial suggestion for selective vulnerability in neurodegenerative diseases. | Hardy J | β | 2016 | β |
| Decoding ALS: from genes to mechanism. | Taylor JP et al. | β | 2016 | β |
| Frontotemporal dementia: insights into the biological underpinnings of disease through gene co-expression network analysis. | Ferrari R et al. | β | 2016 | β |
| Frontotemporal Lobar Degeneration and MicroRNAs. | Piscopo P et al. | β | 2016 | β |
| Genetics of FTLD: overview and what else we can expect from genetic studies. | Pottier C et al. | β | 2016 | β |
| Genome-wide estimate of the heritability of Multiple System Atrophy. | Federoff M et al. | β | 2016 | β |
| Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. | Busch JI et al. | β | 2016 | β |
| Intramembrane proteolysis within lysosomes. | SchrΓΆder B et al. | β | 2016 | β |
| "New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). | Nelson PT et al. | β | 2016 | β |
| NMNAT2:HSP90 Complex Mediates Proteostasis in Proteinopathies. | Ali YO et al. | β | 2016 | β |
| Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. | Teunissen CE et al. | β | 2016 | β |
| Paving the road for the study of epigenetics in neurodegenerative diseases. | Harari O et al. | β | 2016 | β |
| Progranulin Controls Sepsis via C/EBPΞ±-Regulated Il10 Transcription and Ubiquitin Ligase/Proteasome-Mediated Protein Degradation. | Yan W et al. | β | 2016 | β |
| The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death. | Suzuki H et al. | β | 2016 | β |
| What we know about TMEM106B in neurodegeneration. | Nicholson AM et al. | β | 2016 | β |
| A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. | Ferrari R et al. | β | 2015 | β |
| A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy. | Chen JA et al. | β | 2015 | β |
| Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. | Beach TG et al. | β | 2015 | β |
| Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. | Bieniek KF et al. | β | 2015 | β |
| Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). | Lattante S et al. | β | 2015 | β |
| Epidemiology and molecular mechanism of frontotemporal lobar degeneration/amyotrophic lateral sclerosis with repeat expansion mutation in C9orf72. | Ishiura H et al. | β | 2015 | β |
| Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans. | Grapci AD et al. | β | 2015 | β |
| Frontotemporal dementia: a bridge between dementia and neuromuscular disease. | Ng AS et al. | β | 2015 | β |
| Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. | Clayton EL et al. | β | 2015 | β |
| Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. | Irwin DJ et al. | β | 2015 | β |
| FTD and ALS--translating mouse studies into clinical trials. | Ittner LM et al. | β | 2015 | β |
| Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. | Adams HH et al. | β | 2015 | β |
| Genetics and underlying pathology of dementia. | Ferencz B et al. | β | 2015 | β |
| Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. | Gijselinck I et al. | β | 2015 | β |
| Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. | Swanson CR et al. | β | 2015 | β |
| Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. | Benussi A et al. | β | 2015 | β |
| Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. | Nelson PT et al. | β | 2015 | β |
| Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. | Lashley T et al. | β | 2015 | β |
| The role of RNA metabolism in neurological diseases. | Alaqeel AM et al. | β | 2015 | β |
| The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. | Lill CM et al. | β | 2015 | β |
| The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis. | Cooper-Knock J et al. | β | 2015 | β |
| The TMEM106B locus and TDP-43 pathology in older persons without FTLD. | Yu L et al. | β | 2015 | β |
| TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III. | Jun MH et al. | β | 2015 | β |
| Update on Hippocampal Sclerosis. | Dutra JR et al. | β | 2015 | β |
| A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. | Toledo JB et al. | β | 2014 | β |
| Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. | Davidson YS et al. | β | 2014 | β |
| C9orf72; abnormal RNA expression is the key. | Heutink P et al. | β | 2014 | β |
| C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis. | Diekstra FP et al. | β | 2014 | β |
| C9ORF72: grabbing a tiger by the tail. | Mann D | β | 2014 | β |
| C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity. | Yokoyama JS et al. | β | 2014 | β |
| Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. | GΓΆtzl JK et al. | β | 2014 | β |
| Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations andΒ C9orf72 repeat expansions. | Lattante S et al. | β | 2014 | β |
| Dissection of genetic factors associated with amyotrophic lateral sclerosis. | Leblond CS et al. | β | 2014 | β |
| Evidence of the innate antiviral and neuroprotective properties of progranulin. | Suh HS et al. | β | 2014 | β |
| Frontotemporal dementia and its subtypes: a genome-wide association study. | Ferrari R et al. | β | 2014 | β |
| Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. | McMillan CT et al. | β | 2014 | β |
| Genome-wide association studies in neurology. | Tan MS et al. | β | 2014 | β |
| Identification of misdiagnosed fronto-temporal dementia using APOE genotype and phenotype-genotype correlation analyses. | HernΓ‘ndez I et al. | β | 2014 | β |
| Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. | Stagi M et al. | β | 2014 | β |
| Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. | Maffioletti E et al. | β | 2014 | β |
| Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia. | Stepto A et al. | β | 2014 | β |
| Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment. | Suh HS et al. | β | 2014 | β |
| Progranulin in neurodegenerative disease. | Petkau TL et al. | β | 2014 | β |
| Progranulin protein levels are differently regulated in plasma and CSF. | Nicholson AM et al. | β | 2014 | β |
| Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase-like 2a (SPPL2a). | Brady OA et al. | β | 2014 | β |
| RNA-protein interactions in unstable microsatellite diseases. | Mohan A et al. | β | 2014 | β |
| Stuck in traffic: an emerging theme in diseases of the nervous system. | Neefjes J et al. | β | 2014 | β |
| The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. | Gascon E et al. | β | 2014 | β |
| The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. | Schwenk BM et al. | β | 2014 | β |
| Therapeutic and diagnostic challenges for frontotemporal dementia. | D'Alton S et al. | β | 2014 | β |
| The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. | Cooper-Knock J et al. | β | 2014 | β |
| TiME for TMEM106B. | Debaisieux S et al. | β | 2014 | β |
| TMEM106B and APOE polymorphisms interact to confer risk for late-onset Alzheimer's disease in Han Chinese. | Lu RC et al. | β | 2014 | β |
| TMEM106B: a strong FTLD disease modifier. | Deming Y et al. | β | 2014 | β |
| TMEM106B expression is reduced in Alzheimer's disease brains. | Satoh J et al. | β | 2014 | β |
| TMEM106B influences volume of left-sided temporal lobe and interhemispheric structures in the general population. | Adams HH et al. | β | 2014 | β |
| TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. | Gallagher MD et al. | β | 2014 | β |
| TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. | van Blitterswijk M et al. | β | 2014 | β |
| Transmembrane protein 106A is silenced by promoter region hypermethylation and suppresses gastric cancer growth by inducing apoptosis. | Xu D et al. | β | 2014 | β |
| Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice. | Yang Y et al. | β | 2014 | β |
| Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach. | Kumar A et al. | β | 2013 | β |
| A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. | van der Zee J et al. | β | 2013 | β |
| Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: a meta-analysis. | Rubino E et al. | β | 2013 | β |
| Batten disease: clinical aspects, molecular mechanisms, translational science, and future directions. | Dolisca SB et al. | β | 2013 | β |
| Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. | Irwin DJ et al. | β | 2013 | β |
| Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. | Ling SC et al. | β | 2013 | β |
| Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. | Cruts M et al. | β | 2013 | β |
| Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. | Mann DM et al. | β | 2013 | β |
| Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. | Busch JI et al. | β | 2013 | β |
| Genetic insights in Alzheimer's disease. | Bettens K et al. | β | 2013 | β |
| Genome-wide association study of Tourette's syndrome. | Scharf JM et al. | β | 2013 | β |
| hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. | Mori K et al. | β | 2013 | β |
| Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. | Chapuis J et al. | β | 2013 | β |
| Mechanisms of granulin deficiency: lessons from cellular and animal models. | Kleinberger G et al. | β | 2013 | β |
| Molecular signature of disease onset in granulin mutation carriers: a gene expression analysis study. | Milanesi E et al. | β | 2013 | β |
| NMNATs, evolutionarily conserved neuronal maintenance factors. | Ali YO et al. | β | 2013 | β |
| Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration. | Chiang HH et al. | β | 2013 | β |
| Progranulin: at the interface of neurodegenerative and metabolic diseases. | Nguyen AD et al. | β | 2013 | β |
| Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. | Prunotto M et al. | β | 2013 | β |
| The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. | Smith BN et al. | β | 2013 | β |
| The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. | Brady OA et al. | β | 2013 | β |
| The genetics of dementia. | Farlow JL et al. | β | 2013 | β |
| The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. | Ridolfi E et al. | β | 2013 | β |
| TMEM106B and frontotemporal lobar degeneration: can over-expression tell us how reductions are beneficial? | Barger SW | β | 2013 | β |
| A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. | Gijselinck I et al. | β | 2012 | β |
| Advances in understanding the molecular basis of frontotemporal dementia. | Rademakers R et al. | β | 2012 | β |
| Analysis of optineurin in frontotemporal lobar degeneration. | Rollinson S et al. | β | 2012 | β |
| A quantitative study of the neuropathology of 32 sporadic and familial cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). | Armstrong RA et al. | β | 2012 | β |
| Chromosome 9 ALS and FTD locus is probably derived from a single founder. | Mok K et al. | β | 2012 | β |
| Circulating progranulin as a biomarker for neurodegenerative diseases. | Ghidoni R et al. | β | 2012 | β |
| Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. | Stewart H et al. | β | 2012 | β |
| Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. | Hsiung GY et al. | β | 2012 | β |
| Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. | Coppola G et al. | β | 2012 | β |
| Expanding the genetics of amyotrophic lateral sclerosis and frontotemporal dementia. | Schymick JC et al. | β | 2012 | β |
| Familial Lund frontotemporal dementia caused by C9ORF72 hexanucleotide expansion. | Englund E et al. | β | 2012 | β |
| Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. | Majounie E et al. | β | 2012 | β |
| Frontotemporal dementia: implications for understanding Alzheimer disease. | Goedert M et al. | β | 2012 | β |
| Frontotemporal Lobar Degeneration. | Premi E et al. | β | 2012 | β |
| Frontotemporal lobar degeneration: current knowledge and future challenges. | Cerami C et al. | β | 2012 | β |
| Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. | Seltman RE et al. | β | 2012 | β |
| Genetics of frontotemporal lobar degeneration. | Galimberti D et al. | β | 2012 | β |
| Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. | Mead S et al. | β | 2012 | β |
| Identification of pharmacological targets in amyotrophic lateral sclerosis through genomic analysis of deregulated genes and pathways. | Paratore S et al. | β | 2012 | β |
| Investigation of c9orf72 in 4 neurodegenerative disorders. | Xi Z et al. | β | 2012 | β |
| Losing protein in the brain: the case of progranulin. | Ghidoni R et al. | β | 2012 | β |
| Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. | Lang CM et al. | β | 2012 | β |
| Next frontiers in the genetic epidemiology of Alzheimer's disease. | Ikram MA et al. | β | 2012 | β |
| Progranulin: a growth factor, a novel TNFR ligand and a drug target. | Liu CJ et al. | β | 2012 | β |
| Progranulin: an emerging target for FTLD therapies. | Gass J et al. | β | 2012 | β |
| Progranulin axis and recent developments in frontotemporal lobar degeneration. | Nicholson AM et al. | β | 2012 | β |
| Road to the chromosome 9p-linked ALS/FTD locus. | Traynor BJ | β | 2012 | β |
| Stratification-score matching improves correction for confounding by population stratification in case-control association studies. | Epstein MP et al. | β | 2012 | β |
| The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. | SimΓ³n-SΓ‘nchez J et al. | β | 2012 | β |
| The genetics and neuropathology of amyotrophic lateral sclerosis. | Al-Chalabi A et al. | β | 2012 | β |
| The genetics and neuropathology of frontotemporal lobar degeneration. | Sieben A et al. | β | 2012 | β |
| The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. | Van Langenhove T et al. | β | 2012 | β |
| TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. | Rutherford NJ et al. | β | 2012 | β |
| TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. | Chen-Plotkin AS et al. | β | 2012 | β |
| A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. | Renton AE et al. | β | 2011 | β |
| Alzheimer's disease genetics: current knowledge and future challenges. | Hollingworth P et al. | β | 2011 | β |
| Alzheimer's genetics in the GWAS era: a continuing story of 'replications and refutations'. | Bertram L | β | 2011 | β |
| An algorithm for genetic testing of frontotemporal lobar degeneration. | Goldman JS et al. | β | 2011 | β |
| ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. | Meyer NJ et al. | β | 2011 | β |
| Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. | Cruchaga C et al. | β | 2011 | β |
| Biomarkers in frontotemporal lobar degenerations--progress and challenges. | Hu WT et al. | β | 2011 | β |
| Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. | Murray ME et al. | β | 2011 | β |
| Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. | DeJesus-Hernandez M et al. | β | 2011 | β |
| Family history of neurodegenerative and vascular diseases in ALS: a population-based study. | Huisman MH et al. | β | 2011 | β |
| Frontotemporal dementia: from Mendelian genetics towards genome wide association studies. | Ferrari R et al. | β | 2011 | β |
| Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. | Rollinson S et al. | β | 2011 | β |
| Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. | Chen-Plotkin AS et al. | β | 2011 | β |
| Genetics of dementia. | Paulson HL et al. | β | 2011 | β |
| Human genetics as a tool to identify progranulin regulators. | Nicholson AM et al. | β | 2011 | β |
| Modelling the effects of penetrance and family size on rates of sporadic and familial disease. | Al-Chalabi A et al. | β | 2011 | β |
| p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. | Al-Sarraj S et al. | β | 2011 | β |
| Progranulin and TDP-43: mechanistic links and future directions. | Kumar-Singh S | β | 2011 | β |
| Progranulin: a promising therapeutic target for rheumatoid arthritis. | Liu CJ | β | 2011 | β |
| Recent insights into the involvement of progranulin in frontotemporal dementia. | Sun L et al. | β | 2011 | β |
| Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. | Vass R et al. | β | 2011 | β |
| TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration. | Fiesel FC et al. | β | 2011 | β |
| TDP-43 in aging and Alzheimer's disease - a review. | Wilson AC et al. | β | 2011 | β |
| The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. | Tang W et al. | β | 2011 | β |
| TMEM106B a novel risk factor for frontotemporal lobar degeneration. | van der Zee J et al. | β | 2011 | β |
| TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. | van der Zee J et al. | β | 2011 | β |
| TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. | Finch N et al. | β | 2011 | β |
| Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. | Laaksovirta H et al. | β | 2010 | β |
| Chromosome 9p21 in amyotrophic lateral sclerosis: the plot thickens. | Daoud H et al. | β | 2010 | β |
| Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. | Shatunov A et al. | β | 2010 | β |
| Deciphering genetic susceptibility to frontotemporal lobar dementia. | Lambert JC et al. | β | 2010 | β |
| [FTLD/ALS as TDP-43 proteinopathies]. | Ishihara T et al. | β | 2010 | β |
| Genetic causes of frontotemporal degeneration. | See TM et al. | β | 2010 | β |
| Genetics of frontotemporal lobar degeneration. | Aswathy PM et al. | β | 2010 | β |
| Molecular pathways of frontotemporal lobar degeneration. | Sleegers K et al. | β | 2010 | β |
| TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. | Borroni B et al. | β | 2010 | β |
| TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. | Mackenzie IR et al. | β | 2010 | β |
| The future of genetic research on neurodegeneration. | Van Broeckhoven C | β | 2010 | β |
| TMEM106B is a susceptibility locus for Ftld. | Wood HB | β | 2010 | β |